Literature DB >> 33436817

The effectiveness of Bacopa monnieri (Linn.) Wettst. as a nootropic, neuroprotective, or antidepressant supplement: analysis of the available clinical data.

James M Brimson1,2, Sirikalaya Brimson3, Mani Iyer Prasanth1,2, Premrutai Thitilertdecha4, Dicson Sheeja Malar1,2, Tewin Tencomnao5,6.   

Abstract

Bacopa monnieri (Linn.) Wettst. has been used in traditional medicine as a drug to enhance and improve memory. In this regard, this study aims to provide B. monnieri's efficacy as a neuroprotective drug and as a nootropic against various neurological diseases. Literatures were collected, following Prisma guidelines, from databases, including Scopus, PubMed, Google Scholar, and Science Direct and were scrutinized using a quality scoring system. Means, standard deviations and 'n' numbers were extracted from the metrics and analyzed. Jamovi computer software for Mac was used to carry out the meta-analysis. The selected studies suggested that the plant extracts were able to show some improvements in healthy subjects which were determined in Auditory Verbal Learning Task, digit span-reverse test, inspection time task and working memory, even though it was not significant, as no two studies found statistically significant changes in the same two tests. B. monnieri was able to express modest improvements in subjects with memory loss, wherein only a few of the neuropsychological tests showed statistical significance. B. monnieri in a cocktail with other plant extracts were able to significantly reduce the effects of Alzheimer's disease, and depression which cannot be solely credited as the effect of B. monnieri. Although in one study B. monnieri was able to potentiate the beneficial effects of citalopram; on the whole, currently, there are only limited studies to establish the memory-enhancing and neuroprotective effects of B. monnieri. More studies have to be done in the future by comparing the effect with standard drugs, in order to establish these effects clinically in the plant and corroborate the preclinical data.

Entities:  

Year:  2021        PMID: 33436817      PMCID: PMC7803732          DOI: 10.1038/s41598-020-80045-2

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  79 in total

1.  Antipsychotic effects and tolerability of the sigma ligand EMD 57445 (panamesine) and its metabolites in acute schizophrenia: an open clinical trial.

Authors:  M J Müller; G Gründer; H Wetzel; F Müller-Siecheneder; P Marx-Dannigkeit; O Benkert
Journal:  Psychiatry Res       Date:  1999-12-27       Impact factor: 3.222

2.  Short-Term Impact of a Combined Nutraceutical on Cognitive Function, Perceived Stress and Depression in Young Elderly with Cognitive Impairment: A Pilot, Double-Blind, Randomized Clinical Trial.

Authors:  A F Cicero; M Bove; A Colletti; M Rizzo; F Fogacci; M Giovannini; C Borghi
Journal:  J Prev Alzheimers Dis       Date:  2017

3.  Management of cognitive determinants in senile dementia of Alzheimer's type: therapeutic potential of a novel polyherbal drug product.

Authors:  Ananya Sadhu; Prabhat Upadhyay; Aruna Agrawal; Kaliappan Ilango; Dipankar Karmakar; Gur Prit Inder Singh; Govind Prasad Dubey
Journal:  Clin Drug Investig       Date:  2014-12       Impact factor: 2.859

4.  Brain-derived neurotrophic factor (BDNF) changes in the serum of depressed women.

Authors:  Cigdem Aydemir; Esra Süer Yalcin; Sabahat Aksaray; Cebrail Kisa; Sema Gulen Yildirim; Tayfun Uzbay; Erol Goka
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2006-05-02       Impact factor: 5.067

Review 5.  Initiation and adaptation: a paradigm for understanding psychotropic drug action.

Authors:  S E Hyman; E J Nestler
Journal:  Am J Psychiatry       Date:  1996-02       Impact factor: 18.112

6.  Neuroprotective, Neurotrophic and Anti-oxidative Role of Bacopa monnieri on CUS Induced Model of Depression in Rat.

Authors:  Sourav Kumar; Amal Chandra Mondal
Journal:  Neurochem Res       Date:  2016-08-10       Impact factor: 3.996

7.  Scopolamine induced amnesia is reversed by Bacopa monniera through participation of kinase-CREB pathway.

Authors:  Manish Kumar Saraf; Akshay Anand; Sudesh Prabhakar
Journal:  Neurochem Res       Date:  2009-09-16       Impact factor: 3.996

Review 8.  Ageing populations: the challenges ahead.

Authors:  Kaare Christensen; Gabriele Doblhammer; Roland Rau; James W Vaupel
Journal:  Lancet       Date:  2009-10-03       Impact factor: 79.321

9.  Randomized controlled trial of standardized Bacopa monniera extract in age-associated memory impairment.

Authors:  Sangeeta Raghav; Harjeet Singh; P K Dalal; J S Srivastava; O P Asthana
Journal:  Indian J Psychiatry       Date:  2006-10       Impact factor: 1.759

10.  Efficacy of Standardized Extract of Bacopa monnieri (Bacognize®) on Cognitive Functions of Medical Students: A Six-Week, Randomized Placebo-Controlled Trial.

Authors:  Navneet Kumar; L G Abichandani; Vijay Thawani; K J Gharpure; M U R Naidu; G Venkat Ramana
Journal:  Evid Based Complement Alternat Med       Date:  2016-10-10       Impact factor: 2.629

View more
  3 in total

Review 1.  Novel Pharmacological Approaches to the Treatment of Depression.

Authors:  Elias Elias; Ariel Y Zhang; Melissa T Manners
Journal:  Life (Basel)       Date:  2022-01-28

Review 2.  Use of Bacopa monnieri in the Treatment of Dementia Due to Alzheimer Disease: Systematic Review of Randomized Controlled Trials.

Authors:  Aneesh Basheer; Ayush Agarwal; Biswamohan Mishra; Anu Gupta; Madakasira Vasantha Padma Srivastava; Richard Kirubakaran; Venugopalan Vishnu
Journal:  Interact J Med Res       Date:  2022-08-01

3.  Bacopaside-I Alleviates the Detrimental Effects of Acute Paraquat Intoxication in the Adult Zebrafish Brain.

Authors:  Surendra Kumar Anand; Manas Ranjan Sahu; Amal Chandra Mondal
Journal:  Neurochem Res       Date:  2021-08-06       Impact factor: 3.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.